CSIMarket
 


Soligenix inc   (SNGX)
Other Ticker:  
 

Soligenix Inc 's Leverage Ratio

SNGX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 2.73%, Leverage Ratio fell to 2.84, below the Soligenix Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 135 other companies have achieved lower Leverage Ratio than Soligenix Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 1798, from total ranking in the third quarter 2023 at 2402 .

Explain Leverage Ratio?
Who are SNGX Customers?
What are SNGX´s Total Liabilities?


SNGX Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change - 309.03 % -62.81 % - -
Y / Y Total Liabilities Change -57.02 % -58.83 % -43.09 % 1.81 % 3.77 %
Leverage Ratio MRQ 2.84 1.65 1.36 - -
SNGX's Total Ranking # 1798 # 2402 # 2098 # 0 # 0
Seq. Equity Change -40.24 % -27.22 % - - -
Seq. Total Liabilities Change 2.73 % -11.98 % -44.98 % -13.61 % -1.62 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 330
Overall Market # 1798


Leverage Ratio Statistics
High Average Low
158.83 8.33 0.39
(Jun 30 2016)   (Dec 31 2016)




Financial Statements
Soligenix Inc 's Equity $ 3 Millions Visit SNGX's Balance sheet
Soligenix Inc 's Total Liabilities $ 7 Millions Visit SNGX's Balance sheet
Source of SNGX's Sales Visit SNGX's Sales by Geography


Cumulative Soligenix Inc 's Leverage Ratio

SNGX's Leverage Ratio for the trailling 12 Months

SNGX Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth - 309.03 % -62.81 % - -
Y / Y Total Liabilities TTM Growth -57.02 % -58.83 % -43.09 % 1.81 % 3.77 %
Leverage Ratio TTM 3.98 11.02 57.32 5.74 1.96
Total Ranking TTM # 22 # 361 # 1151 # 18 # 10
Seq. Equity TTM Growth -40.24 % -27.22 % - - -
Seq. Total Liabilities TTM Growth 2.73 % -11.98 % -44.98 % -13.61 % -1.62 %


On the trailing twelve months basis Despite of the net new borrowings of 2.73% during the twelve months period ending in IV Quarter 2023 Soligenix Inc has managed to decrease Leverage Ratio in the IV Quarter 2023 to 3.98, below Soligenix Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 6, during the past 12 months, other companies have achieved lower Leverage Ratio than Soligenix Inc . While Leverage Ratio total ranking has improved so far to 22, from total ranking in previous 12 month period at 361.

Explain Leverage Ratio?
Who are SNGX Customers?
What are SNGX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 8
Within the Market # 22


trailing twelve months Leverage Ratio Statistics
High Average Low
57.66 4.84 0.57
(Jun 30 2023)   (Sep 30 2017)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Blueprint Medicines Corporation  7.03 $ 918.641  Millions$ 130.609  Millions
Ionis Pharmaceuticals Inc  6.73 $ 2,603.386  Millions$ 386.686  Millions
Bio path Holdings inc   6.30 $ 2.779  Millions$ 0.441  Millions
Mersana Therapeutics Inc   5.13 $ 189.156  Millions$ 36.904  Millions
Biofrontera Inc   4.83 $ 23.139  Millions$ 4.793  Millions
Collegium Pharmaceutical Inc   4.82 $ 941.753  Millions$ 195.431  Millions
Eli Lilly And Company  4.69 $ 50,993.800  Millions$ 10,863.700  Millions
Gossamer Bio Inc   3.97 $ 249.147  Millions$ 62.769  Millions
Amicus Therapeutics inc   3.86 $ 617.706  Millions$ 160.174  Millions
Biolinerx Ltd   3.83 $ 50.702  Millions$ 13.223  Millions
Teva Pharmaceutical Industries Limited  3.65 $ 29,667.000  Millions$ 8,126.000  Millions
Milestone Pharmaceuticals inc   3.49 $ 58.455  Millions$ 16.771  Millions
Travere Therapeutics Inc   2.93 $ 588.103  Millions$ 200.810  Millions
Clene Inc   2.91 $ 38.951  Millions$ 13.390  Millions
Arcutis Biotherapeutics Inc   2.85 $ 252.698  Millions$ 88.667  Millions
Soligenix inc   2.84 $ 7.153  Millions$ 2.522  Millions
Aytu Biopharma Inc   2.80 $ 92.052  Millions$ 32.853  Millions
G1 Therapeutics Inc   2.43 $ 86.154  Millions$ 35.386  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Phibro Animal Health Corporation  2.31 $ 626.625  Millions$ 270.803  Millions
Vaxxinity Inc   2.30 $ 30.902  Millions$ 13.409  Millions
Bristol myers Squibb Company  2.23 $ 65,729.000  Millions$ 29,485.000  Millions
Eyenovia inc   2.05 $ 18.488  Millions$ 8.999  Millions
Alimera Sciences Inc   2.00 $ 92.218  Millions$ 46.170  Millions
Biovie Inc   1.87 $ 13.981  Millions$ 7.491  Millions
Zoetis Inc   1.86 $ 9,289.000  Millions$ 4,991.000  Millions
Emergent Biosolutions Inc   1.81 $ 1,173.900  Millions$ 649.300  Millions
Jazz Pharmaceuticals Plc  1.78 $ 6,644.680  Millions$ 3,736.997  Millions
Catalent Inc   1.71 $ 6,301.000  Millions$ 3,687.000  Millions
Xoma Corporation  1.64 $ 145.580  Millions$ 88.721  Millions

Date modified: 2024-03-18T20:26:16+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com